Pharmaceuticals & Biotechnology | Pharma & Biotech Resources

Mark Walls, Director of Clinical Pharmacy at Human Genome Sciences, speaks to Andrea Charles from Pharma IQ, about the logistical challenges facing clinical trials and avoiding common mistakes for logistics in emerging countries. He also talks about the need for pharmaceutical and

In this exclusive interview, Dr. Sylviane Boucharens, Section Head of Molecular Pharmacology Department at MSD, speaks to Andrea Charles from Pharma IQ, about the current hurdles to accurate compound management and integrity, and the  benefits of outsourcing all or part

According to Transparency International's Bribe Payers Index, among 19 industry sectors globally, life sciences is perceived to be the 6th most corrupt sector, in terms of the propensity of companies to pay bribes. In this exclusive interview Chandrashekhar Krishnan, Executive

Daniel Schick, Executive Director, Commercial Affairs & Key Account Management for Janssen-Cilag, spoke to Andrea Charles from Pharma IQ, about the current challenges facing pharmaceutical sales force effectiveness. In this podcast, he shares his insights on the

Dr. Steffen Renner, Investigator II, Molecular and Library Informatics at Novartis Pharma AG, speaks to Andrea Charles from Pharma IQ, about the current challenges relating to compound storage and retrieval and how are these issues affecting the success of HTS programs. In this

In this Pharma IQ podcast, Isabel Henkel, Director, Access & Reimbursement at Johnson & Johnson Medical, talks about how the pharma industry needs to adjust to the new requirements of the German government’s pharmaceutical savings programme (Arzneitmittelsparpaket),

How can we overcome the latest challenges in Biomarker Development? Birgitte Søgaard, Divisional Director for Clinical Pharmacology and Translational Medicine at H Lundbeck A/S, discusses with Helen Winsor from Pharma IQ, the key challenges in this area, in particular the

Hören Sie hier ein exklusives Interview mit Dr. Elizabeth Storz, Referentin Arzneimittelsicherheit beim vfa - Verband der forschenden Pharma-Unternehmen, zum Thema 'Auswirkungen des EU-Pharma Pakets auf die Pharmakovigilanz'.

How do you deliver a vaccine that can only cost a dollar, to the whole population of a country, and still make a profit for the pharmaceutical company that is developing it? Dr. Donald Francis vaccine pioneer and Executive Director of Global Solutions for Infectious Diseases (GSID),

Pharmacists are the last player in the distribution chain, and the ones who have the most interaction with the patient. John Chave, Secretary General of the Pharmaceutical Group of the European Union, speaks to Andrea Charles from Pharma IQ, about the current challenges relating to

Dr. Franz Hessel, Director of International Health Economics Outcomes Research at Abbott, talks to Andrea Charles from Pharma IQ, about the  approaches authorities in leading pharmaceutical markets have taken to the use of Health Technology Assessment (HTA) and h

Pharma IQ is joined by Mark Divers, Executive Director, KI Biobank at Karolinska Institute, to discuss some of the prevalent aspects in the growing field of biobanking, from international partnerships to standardising protocol.

Dr. Andy Bell, Research Fellow at Sandwich Laboratories Worldwide R&D, Pfizer, shares his insights on Pfizer's review of their screening file, prior to the merger with Wyeth in 2009. He also discusses with Pharma IQ, how they identified areas where

Pharma IQ caught up with Dr. Wolfgang Schmitt, Business Development Manager Pharma at IDS Scheer, to discuss the challenges which arise when optimising supply chains and how we should seek  to improve S&OP.

Dr. Morten Rosted, Head of Department, DK Patents, Corporate Patents & Trademarks at H. Lundbeck A/S, speaks to Pharma IQ about the spectrum of capabilities needed in biopatent design and how to build a robust patent strategy.